The Novel Coronavirus 2019, was first reported on in Wuhan, China in late December 2019.  The outbreak was declared a public health emergency of international concern in January 2020 and on March 11th, 2020, the outbreak was declared a global pandemic.  The spread of this virus is now global with lots of media attention.  The virus has been named SARS-CoV-2 and the disease it causes has become known as coronavirus disease 2019 (COVID-19). This new outbreak has been producing lots of hysteria and false truths being spread, however the data surrounding the biology, epidemiology, and clinical characteristics are growing daily, making this a moving target.

REBEL COVID-19

will serve as a summary of what is currently known, how to screen, when to test, and how to prevent spread, and any new data/information on COVID-19.

  • All Categories
  • REBEL Covid-19
All Categories
  • All Categories
  • REBEL Covid-19

REBEL Cast Ep110: The COVI-PRONE Trial – Awake Prone Positioning and COVID-19

Background: Early in the COVID-19 pandemic, clinicians were looking for practical, widely available, and low-cost interventions to help patients with hypoxemia.  One of those interventions was awake prone positioning.  Potential mechanisms of benefit in awake proning include more uniform distribution …

Read More
Infectious DiseaseThoracic and Respiratory

SSRIs and COVID-19

Background: The effects of the COVID-19 pandemic have been devastating. Given the novelty of the virus, only a few effective treatments have emerged to decrease mortality from SARS-CoV-2 infection. The morbidity and mortality of SARS-CoV-2 is thought to be due …

Read More
Infectious Disease

The INSPIRATION Trial: Intermediate Dose Anticoagulation in Critically Ill Patients with COVID-19

Background: COVID-19 infection increases the risk of thrombosis due to multiple factors.(Rico-Mesa, 2020). Over the last 2 years, researchers have published 12 RCTs investigating various anticoagulation strategies among patients diagnosed with COVID-19 in multiple clinical settings. To date, only a multiplatform …

Read More
CardiovascularHematology and OncologyInfectious DiseaseThoracic and Respiratory

The COV-BOOST Trial: Safety and Immunogenicity of Boosters

Background: COVID-19 became an international pandemic in March of 2020, claiming the lives of millions of people worldwide. To combat this deadly virus, an unprecedented global effort led to the development of many new vaccines against COVID-19 within a year. …

Read More
Infectious DiseaseThoracic and Respiratory

The ACTION Trial: DOACs in Hospitalized Patients with COVID-19

Background: Patients hospitalized with COVID-19 are at increased risk for both arterial and venous thromboembolic disease. Multiple recent trials have investigated the efficacy of therapeutic or standard prophylactic anticoagulation in preventing thrombotic complications among patients with COVID-19 in a variety …

Read More
CardiovascularInfectious DiseaseThoracic and Respiratory

The MICHELLE Trial: Anticoagulation Post-Discharge in Patients Hospitalized Secondary to COVID-19

Background: Patients diagnosed with COVID-19 have an increased risk of thromboembolic events, including pulmonary embolism and deep vein thrombosis (DVT). In addition, COVID-19 patients with increased coagulation parameters such as D-dimer, fibrin degradation products, prothrombin time, and activated partial thromboplastin …

Read More
CardiovascularHematology and OncologyInfectious DiseaseThoracic and Respiratory

The MOVe-Out Trial: Molnupiravir – Oral Antivirals for Management of Covid-19?

Background: On December 23, 2021, the FDA granted molnupiravir emergency use authorization for the treatment of patients with Covid-19. Molnupiravir is a nucleoside analog that inhibits SARS-CoV-2 replication and triggers viral RNA mutagenesis. Until the release of oral antivirals, clinicians …

Read More

The ACTIV-4b Trial: Antithrombotics For Treatment of Outpatient COVID-19

Background: Severely ill patients diagnosed with COVID-19 have an increased risk of cardiovascular complications, especially thromboembolic events (Bikdeli 2020). The overall incidence of developing venous thromboembolism (VTE) is approximately 17% in patients diagnosed with COVID-19, with a significantly higher rate …

Read More
Thoracic and Respiratory

COV-BARRIER Addendum Study: Baricitinib in ECMO/Mechanically Ventilated Patients with COVID-19

Background:  Despite access to vaccines in developed countries, COVID19 remains a nimble and persistent foe. While case counts wax and wane the virus continues to spread and mutate. The rapid development of vaccines has been helpful but the distribution across …

Read More
Infectious DiseaseThoracic and Respiratory

The HEP-COVID Trial: Therapeutic Anticoagulation in Non-Critically Ill COVID-19 Patients

Background: Patients with COVID-19 are at increased risk from thromboembolic phenomena. Patient-specific factors such as comorbidities and immobility have been linked to thrombosis. Disease-specific factors such as virus-induced endothelial changes and cytokine storm may also be triggers. Furthermore, patients with elevated …

Read More
Hematology and OncologyInfectious DiseaseThoracic and Respiratory

Sponsored

0